PolyMedica Industries Inc., et al.; Withdrawal of Approval of Three New Drug Applications
The Food and Drug Administration (FDA) is withdrawing approval of three new drug applications (NDAs) from multiple holders of those NDAs. The basis for the withdrawal is that th...
The Food and Drug Administration (FDA) is withdrawing approval of three new drug applications (NDAs) from multiple holders of those NDAs. The basis for the withdrawal is that these NDA holders have repeatedly failed to file required annual reports for those NDAs.
DATES:
Approval is withdrawn as of September 13, 2021.
FOR FURTHER INFORMATION CONTACT:
Kimberly S. Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137,
Kimberly.Lehrfeld@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
The holder of an approved application to market a new drug for human use is required to submit annual reports to FDA concerning its approved application in accordance with § 314.81 (21 CFR 314.81).
In the
Federal Register
of March 3, 2021 (86 FR 12474), FDA published a notice offering an opportunity for a hearing (NOOH) on a proposal to withdraw approval of those NDAs because the holders of those NDAs had repeatedly failed to submit the required annual reports for those NDAs. The holders of the NDAs identified in table 1 did not respond to the NOOH. Failure to file a written notice of participation and request for hearing as required by § 314.200 (21 CFR 314.200) constitutes an election by those holders of the NDAs not to make use of the opportunity for a hearing concerning the proposal to withdraw approval of their NDAs and a waiver of any contentions concerning the legal status of the drug products. Therefore, FDA is withdrawing approval of the three applications listed in table 1.
Table 1—Approved NDAs for Which Required Reports Have Not Been Submitted
FDA finds that the holders of the NDAs listed in table 1 have repeatedly failed to submit reports required by § 314.81. In addition, under § 314.200, FDA finds that the holders of the NDAs have waived any contentions concerning the legal status of the drug products. Therefore, under these findings, approval of the NDAs listed in table 1 and all amendments and supplements thereto is hereby withdrawn as of September 13, 2021.
( printed page 50887)
Dated: September 3, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
Use this for formal legal and research references to the published document.
86 FR 50886
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“PolyMedica Industries Inc., et al.; Withdrawal of Approval of Three New Drug Applications,” thefederalregister.org (September 13, 2021), https://thefederalregister.org/documents/2021-19689/polymedica-industries-inc-et-al-withdrawal-of-approval-of-three-new-drug-applications.
21 CFR 314.81